XXX XXXXX AND COMPANY. By: ------------------------------------- Name: Title: Attest: By: ---------------------------- Name: Title: Exhibit B Form of Right Certificate Certificate No. R- _________ Rights NOT EXERCISABLE AFTER JULY 28, 2008 OR EARLIER IF REDEMPTION OR EXCHANGE OCCURS. THE RIGHTS ARE SUBJECT TO REDEMPTION AT $.005 PER RIGHT AND TO EXCHANGE ON THE TERMS SET FORTH IN THE RIGHTS AGREEMENT. Rights Certificate XXX LILLY AND COMPANY This certifies that __________, or registered assigns, is the registered owner of the number of Rights set forth above, each of which entitles the owner thereof, subject to the terms, provisions and conditions of the Rights Agreement, dated as of July 20, 1998 (the "Rights Agreement"), between Xxx Xxxxx and Company, an Indiana corporation (the "Company"), and First Chicago Trust Company of New York (the "Rights Agent"), to purchase from the Company at any time after the Distribution Date (as such term is defined in the Rights Agreement) and prior to 5:00 p.m., New York time, on July 28, 2008 at the principal office of the Rights Agent, or at the office of its successor as Rights Agent, one one-thousandth of a fully paid non-assessable share of Series B Junior Participating Preferred Stock of the Company, without par value (the "Preferred Shares"), at a purchase price of $325 per one one-thousandth of a Preferred Share (the "Purchase Price"), upon presentation and surrender of this Right Certificate with the Form of Election to Purchase duly executed. The number of Rights evidenced by this Right Certificate (and the number of one one-thousandths of a Preferred Share which may be purchased upon exercise hereof) set forth above, and the Purchase Price set forth above, are the number and Purchase Price as of July 20, 1998, based on the Preferred Shares as constituted at such date. As provided in the Rights Agreement, the Purchase Price and the number of one one-thousandths of a Preferred Share which may be purchased upon the exercise of the Rights evidenced by this Right Certificate are subject to modification and adjustment upon the happening of certain events. This Right Certificate is subject to all of the terms, provisions and conditions of the Rights Agreement, which terms, provisions and conditions are hereby incorporated herein by reference and made a part hereof and to which Rights Agreement reference is hereby made for a full description of the rights, limitations of rights, obligations, duties and immunities hereunder of the Rights Age...
XXX XXXXX AND COMPANY. Immunocore Limited, having its principal place of business at 000 Xxxx Xxxxx, Xxxxxx Xxxx, Abingdon, Xxxx, XX00 0XX, Xxxxxx Xxxxxxx (“Immunocore”), and Xxx Xxxxx and Company, Lilly Xxxxxxxxx Xxxxxx, Xxxxxxxxxxxx, Xxxxxxx, 00000, Xxxxxx Xxxxxx of America (“Lilly”) entered into a Development and License Agreement On July 11, 2014 (“the Agreement”). The Parties desire to amend the Agreement to provide for transfer of Material and related confidential and proprietary information between the Parties. This is an Amendment to the Agreement, and this 3rd Amendment is entered into on the last date signed below by the Parties. The Parties are willing to provide each other with such Material and related confidential and proprietary information subject to the terms and conditions stated herein.
XXX XXXXX AND COMPANY. Applied Molecular Evolution, Inc ....... Applied Molecular Evolution, Inc., Xxx Lilly and Company. Xxxxxx KGaA, The Dial Corporation. JLL Partners Fund IV, L.P., Xxxxxxxxx Capital Partners Fund IV, L.P., PGT Holdings Company. MGE Finances SAS, Xxxxxxxxx Elec- tric S.A. Axis Systems, Inc., Verisity Ltd. Cumulus Media Inc., Southern Min- nesota Broadcasting Co. Xxxxxx Associated Companies, Inc., Sylvan Inc. Alcoa ACC Industrial Chemicals Ltd., Alcoa Chemicals Japan Limited, Alcoa Chemie GmbH, Alcoa Chemie Nederland B.V., Aloca Inc., Alcoa World Alumina LLC, Australian Fused Materials Pty Ltd., Discovery Aluminas, Inc., Qingdao Alcoa Co., Ltd., Qingdao Alcoa Trading Co., Ltd., Rhone Capital LLC. Citrix Systems, Inc., Xxxxxxxxxx.xxx.Xxx. Sunshine Network, The News Cor- poration Limited. Compass Partners European Equity Fund (Bermuda) L.P., DBM Group S.A., Drake Beam Xxxxx do Brasil Commercial Ltda., Drake Beam Xxxxx, Inc., Xxxxxxx X. Xxxxxxx. American Central Eastern Texas Gas Company, Ltd Partnership Xxxxxxx X. Xxxxxxx, Xxxxxxx X. Xxxxxx. American Central Eastern Texas Gas Co., Ltd. Partnership, Ste- phen X. Xxxxxxx, Xxxxxxx X. Xxxxxx. Alaska Pipeline Company, LLC, Atlas Pipeline Partners, L.P., SEMCO Energy, Inc. National Medical Health Card Sys- tems, Inc., New Mountain Part- ners, L.P. Summit America Television, Inc., The Xxxxxx X. Scripps Trust. Xxxxx & XxXxxxxx Companies, Inc., Synhrgy HR Technologies, Inc. Gannett Co., Inc., Xxxxxx Publishing L.L.C.
XXX XXXXX AND COMPANY. In June 2000, Xxx Lilly executed a follow-on development agreement to their 1997 multi-year research and option agreement with us to develop oral formulations of Forteo (recombinant parathyroid hormone) and Humatrope (human growth hormone (hGH)) utilizing our proprietary drug delivery technology. Under the new agreement, we will collaborate to bring oral forms of Forteo and Humatrope into clinical testing. The new agreement also provides for supplemental research and development funding. In addition, we received a $2.0 million milestone payment under the terms of the previous agreement. In fiscal 1998, Lilly entered into two license agreements to use our technologies in connection with Forteo and Humatrope and we received a $4.0 million milestone payment. Through July 31, 2000, we have recognized contract research revenues of $10.2 million ($2.2 million, $1.4 million, and $6.6 million in 2000, 1999 and 1998, respectively). Regeneron Pharmaceuticals Inc. During fiscal 2000, we entered into a research collaboration with Regeneron Pharmaceuticals, Inc. to investigate the applicability of our technology to the development of an oral form of Regeneron's protein compound candidate for the treatment of obesity, Axokine. Novartis Pharma AG. In connection with our 1997 research collaboration with Novartis Pharma AG, in fiscal 2000 Novartis agreed to execute its option to acquire an exclusive license to develop and commercialize oral salmon calcitonin. In addition, during fiscal 2000, Novartis agreed to extend its collaboration with us to investigate the oral delivery of a second Novartis compound. In conjunction with the above agreements, Novartis made a $2.5 million cash payment to us during fiscal 2000. Through July 31, 2000, we have recognized contract research revenues of $8.6 million ($3.5 million, $2.9 million, and $2.2 million in 2000, 1999 and 1998, respectively). Feasibility Studies. We have also entered into a number of proof-of-concept studies with additional pharmaceutical and biotechnology companies for various injectable compounds. These feasibility studies are ongoing. Emisphere will continue to pursue additional feasibility studies to determine the potential for further collaborative development programs.
XXX XXXXX AND COMPANY. ACKNOWLEDGMENT OF RIGHTS Xxx Xxxxx and Company (“Xxx Xxxxx”), through its properly authorized officer, hereby acknowledges that it has certain rights that it will be giving up by pleading guilty.
XXX XXXXX AND COMPANY. This Confidential Individual Settlement Agreement and Release of All Claims (hereinafter the “Confidential Release”) is entered into between individually and on behalf of all derivative claimants under applicable law, (hereinafter defined directly below as “Claimant”) and Xxx Lilly and Company (hereinafter “Lilly” as further defined below). This Confidential Release is deemed effective as of (the “Effective Date”).
XXX XXXXX AND COMPANY. GUILTY PLEA AGREEMENT Under Federal Rule of Criminal Procedure 11(c)(1)(C), the government, the defendant, Xxx Xxxxx and Company (hereinafter “Xxx Xxxxx”), and Xxx Xxxxx’x counsel enter into the following guilty plea agreement. Any reference to the United States or the government in this agreement shall mean the Office of the United States Attorney for the Eastern District of Pennsylvania and the Office of Consumer Litigation of the Department of Justice.
XXX XXXXX AND COMPANY. By: ------------------------ August X. Xxxxxxxx Executive Vice President VERTEX PHARMACEUTICALS INCORPORATED By: ------------------------- Xxxxxxx X. Xxxxxxx Senior Vice President and Chief Business Officer Schedule 1.32 to RESEARCH AND DEVELOPMENT AGREEMENT between VERTEX PHARMACEUTICALS INCORPORATED and XXX LILLY AND COMPANY LILLY PATENTS ------------------------------------------------------------------------------- U.S. Patents 4,569,794 Expires December 5, 2004 Title: Process for Purifying Proteins and Compounds Useful in such Process Research and Development Agreement -- Confidential -- Schedule 1.32 Schedule 1.84 to RESEARCH AND DEVELOPMENT AGREEMENT between VERTEX PHARMACEUTICALS INCORPORATED and XXX XXXXX AND COMPANY VERTEX PATENTS ------------------------------------------------------------------------------- HCV NS3 Serine Protease Inhibitor Program VERTEX PATENT APLICATIONS TITLE PATENT NUMBERS COUNTRIES INVENTORS Methods, Nucleotide 08/432,693 US (5/1/95) Su et al. Sequences and (US) Host Cells for PCT (5/1/96) Assaying WO Exogenous and 96/34 Endogenous 976 Protease Activity [*] Research and Development Agreement -- Confidential -- Schedule 1.84 Schedule 2.3(b) to RESEARCH AND DEVELOPMENT AGREEMENT between VERTEX PHARMACEUTICALS INCORPORATED and XXX LILLY AND COMPANY INITIAL MEMBERS OF RESEARCH TEAM ------------------------------------------------------------------------------ VERTEX Xx. Xxxxx Xxxx Dr. Xxxx Xxxxxxx Xx. Xxxxx Xxxx Xx. Xxxx Xxxxxx ONE TO BE DETERMINED Lilly Research Team Members: Xxxxxx X. Xxxxxxxx, Ph.D. HEAD, BIOLOGY FOR INFECTIOUS DISEASES RESEARCH Xxxxxx Xxxxx, Ph.D. RESEARCH FELLOW, VIROLOGY RESEARCH, INFECTIOUS DISEASES Xxxx X. Xxxxxx, Ph.D. HEAD OF CHEMISTRY AND BIOCHEMISTRY, INFECTIOUS DISEASES RESEARCH Xxxxxx X. Xxxxxxxx, M.D. DIRECTOR, INFECTIOUS DISEASES RESEARCH AND DECISION PHASE MEDICAL Research and Development Agreement -- Confidential -- Schedule 2.3(b) Schedule 3.3 to RESEARCH AND DEVELOPMENT AGREEMENT between VERTEX PHARMACEUTICALS INCORPORATED and XXX XXXXX AND COMPANY Hepatitis C Viris (HCV) [*] Inhibitor Program Vertex Research Activities: 1997-2000 -------------------------------------------------------------------------------- The accompanying list summarizes planned Vertex research activities for the design and development of novel, potent inhibitors of the Hepatitis C Virus (HCV) [*]. Changes to this schedule can and will be incorporated based on research findings published in the literature or from Vert...
XXX XXXXX AND COMPANY. By: /s/ Xxxxxx Xxxxxx -------------------- Title: President and Chief Operating Officer LIGAND PHARMACEUTICALS INCORPORATED By: /s/ Xxxxx X. Xxxxxxxx --------------------- Xxxxx X. Xxxxxxxx President and Chief Executive Officer SERAGEN, INC.
XXX XXXXX AND COMPANY. By: /s/ Xxxxxx X. Xxxx --------------------------------------------- Title: Executive Vice President, Science and Technology ----------------------------------------- STRUCTURAL GENOMIX, INC. By: /s/ M. Grey --------------------------------------------- Title: President and CEO ------------------------------------------
